R
Roger Stupp
Researcher at Northwestern University
Publications - 463
Citations - 73077
Roger Stupp is an academic researcher from Northwestern University. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 93, co-authored 430 publications receiving 63025 citations. Previous affiliations of Roger Stupp include Merck & Co. & University of St. Gallen.
Papers
More filters
Journal ArticleDOI
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I–II study
Y. Seium,Roger Stupp,Thomas Ruhstaller,Pascal Gervaz,Gilles Mentha,M. Philippe,Abdelkarim S. Allal,C. Trembleau,J. Bauer,R. Morant,Arnaud Roth +10 more
TL;DR: OCFL is an overall well tolerated regimen with very high efficacy, which makes it most suitable for tumour control before surgery of metastatic disease.
Journal ArticleDOI
EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.
Wolfgang Wick,Alba A. Brandes,Thierry Gorlia,Martin Bendszus,Felix Sahm,Walter Taal,Martin J B Taphoorn,Julien Domont,Ahmed Idbaih,Mario Campone,Paul Clement,Roger Stupp,Michel Fabbro,Emilie Le Rhun,François Dubois,Martin Klein,Michael Platten,Michael Weller,Vassilis Golfinopoulos,Martin J. van den Bent +19 more
TL;DR: EORTC 26101 aimed investigating whether the combination of bevacizumab and lomustine improves OS in patients with first progression of a glioblastoma compared to lomUSTine alone.
Journal ArticleDOI
Epigenetic deregulation of DNA repair and its potential for therapy
TL;DR: Patients whose tumors carry such defects can be stratified for respective therapy rendering some classic DNA damaging agents, such as alkylators or DNA crosslinking agents, into “targeted therapies.”
Journal ArticleDOI
Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
A. Roth,Rudolf Maibach,Stephen Falk,Roger Stupp,Piercarlo Saletti,D. Kaberle,Markus Borner,Hanspeter Honegger,Martin Leslie,Nicola Fazio +9 more
TL;DR: Despite an increased toxicity, docetaxel based regimens seem to be more efficacious than ECF, and in terms of RR and TTP, TCF is the more promising regimen and should be chosen for formal comparison with ECF.
Journal ArticleDOI
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma
Enrico Franceschi,Roger Stupp,Martin J. van den Bent,Carla M.L. van Herpen,Florence Laigle Donadey,Thierry Gorlia,Monika E. Hegi,Benoit Lhermitte,Lewis C. Strauss,Anouk Allgeier,Denis Lacombe,Alba A. Brandes +11 more
TL;DR: In this phase I study of recurrent glioblastoma patients, the combination of CCNU and dasatinib showed significant hematological toxicities and led to suboptimal exposure to both agents.